


DM1-SMe

Cat. No.:	HY-100128
CAS No.:	138148-68-2
Molecular Formula:	C ₃₆ H ₅₀ ClN ₃ O ₁₀ S ₂
Molecular Weight:	784.38
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (127.49 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>1.2749 mL</td> <td>6.3745 mL</td> <td>12.7489 mL</td> </tr> <tr> <td>5 mM</td> <td>0.2550 mL</td> <td>1.2749 mL</td> <td>2.5498 mL</td> </tr> <tr> <td>10 mM</td> <td>0.1275 mL</td> <td>0.6374 mL</td> <td>1.2749 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	1.2749 mL	6.3745 mL	12.7489 mL	5 mM	0.2550 mL	1.2749 mL	2.5498 mL	10 mM	0.1275 mL	0.6374 mL	1.2749 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	1.2749 mL	6.3745 mL	12.7489 mL																		
	5 mM	0.2550 mL	1.2749 mL	2.5498 mL																		
	10 mM	0.1275 mL	0.6374 mL	1.2749 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.19 mM); Clear solution																					

BIOLOGICAL ACTIVITY

Description	DM1-SMe is an unconjugated form of the Maytansinoid in IMG901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC ₅₀ s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines ^[1] .
IC₅₀ & Target	Maytansinoids

REFERENCES

- [1]. Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMG901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. *Pediatr Blood Cancer*. 2013;60(11):1860-1867.
- [2]. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. *Acc Chem Res*. 2008;41(1):98-107.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA